HZNP
Horizon Therapeutics Public Limited Company
Set alert
116.30 0.00 0.00%
116.30 Day range 116.34
52-week range unavailable
- Open
- 116.34
- Prev close
- 116.30
- Mkt cap
- 26.60B
- Vol
- 23.92M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 116.30
- High
- 116.34
- Forward P/E
- 0.00
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 1, 2023
- 50-d avg
- 0.00
- 200-d avg
- 0.00
Key statistics
- Market cap
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- Price / sales
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Next earnings
Nov 1, 2023
Expected Nov 1, 2023. Consensus EPS estimate 0.00.
Financials — quick view
HZNP Revenue — quarterly 944.96M
HZNP Net income — quarterly 127.07M
HZNP EPS — quarterly 0.56
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 1, 2023 | Sep 1, 2023 | 1.22 | — | — | — |
| Aug 8, 2023 | Jun 1, 2023 | 1.12 | — | — | — |
| May 3, 2023 | Mar 1, 2023 | 1.17 | — | — | — |
| Mar 1, 2023 | Dec 1, 2022 | 1.09 | — | — | — |
| Nov 2, 2022 | Sep 1, 2022 | 1.00 | — | — | — |
| Aug 3, 2022 | Jun 1, 2022 | 1.35 | — | — | — |
News
- Amgen: MariTide's Progress, Reassessment Of The Horizon Acquisition
- Amgen quarterly profit rises 15% as Horizon deal boosts results
- Cramer names biopharma companies to watch as industry mergers start to pile up
- 5 Biotech Acquisition Targets To Accumulate In 2024
- Amgen: Horizon's Pipeline May Be Too Expensive
- Amgen completes $27.8 bln Horizon deal
- Horizon Therapeutics (HZNP) Up 10.4% Since Last Earnings Report: Can It Continue?
- 3 Growth Stocks to Buy in September
- The FTC cleared Amgen's $27.8 billion Horizon buyout — here's what it means for other massive pharma deals
- Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement
Your note
Sign in to keep a note on HZNP — it syncs with the Stock Master app.